ELN » Topics » Documents on Display

This excerpt taken from the ELN 6-K filed Mar 30, 2009.
Documents on Display
 
The Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act). In accordance with these requirements, the Company files Annual Reports on Form 20-F with, and furnishes Reports of Foreign Issuer on Form 6-K to, the SEC. These materials, including our Annual Report on Form 20-F for the fiscal year ended 31 December 2008 and the exhibits thereto, may be inspected and copied at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington D.C. 20549. Copies of the materials may be obtained from the Public Reference Room of the SEC at 100 F Street, NE, Room 1580, Washington, D.C., at prescribed rates. The public may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC in the United States at 1-800-SEC-0330. As a foreign private issuer, all documents that were filed or submitted after 4 November 2002 on the SEC’s EDGAR system are available for retrieval on the website maintained by the SEC at http://www.sec.gov. These filings and submissions are also available from commercial document retrieval services.
 
Copies of our Memorandum and Articles of Association may be obtained at no cost by writing or telephoning the Company at our principal executive offices. Our Memorandum and Articles of Association are filed with the SEC as Exhibit 4.1 of our Registration Statement on Form S-8 (SEC File No. 333-135185) filed with the SEC on 21 June 2006. You may also inspect or obtain a copy of our Memorandum and Articles of Association using the procedures prescribed above.

     
192
  Elan Corporation, plc 2008 Annual Report


Table of Contents

 
 
Trademarks
 
 
The following trademarks appearing in this publication are owned by or licensed to the Company:
 
•  Azactam® (aztreonam for injection, USP)
 
•  Maxipime® (cefepime hydrochloride) for injection
 
•  MXDAS® Technology
 
•  NanoCrystal® Technology
 
•  Naprelan® (naproxen sodium controlled-release) tablets
 
•  Prialt® (ziconotide intrathecal infusion)
 
•  SODAS® Technology
 
•  Tysabri® (natalizumab)
 
•  Verelan® (verapamil) capsules
 
Third-party marks appearing in this publication are:
 
•  Adalat®CC (nifedipine) tablets
 
•  Avinza® (morphine sulfate extended-release) capsules
 
•  Avonex® (interferon beta-1A)
 
•  Betaferon® (interferon beta-1b)
 
•  Betaseron® (interferon beta-1b)
 
•  Bidil® XR (isosorbide dinitrate/hydralazine hydrochloride)
 
•  Copaxone® (glatiramer acetate injection)
 
•  Emend® (aprepitant)
 
•  Fampridine SR (4-aminopyride)
 
•  FocalinXR® (dexmethylphenidate)
 
•  LUVOX CR® (fluvoxamine maleate)
 
•  Megace® ES (megastrol acetate)
 
•  Rapamune® (sirolimus)
 
•  Rebif® (interferon-beta-1a)
 
•  Ritalin LA® (methylphenidate hydrochloride) tablets
 
•  Skelaxin® (metaxalone) tablets
 
•  Sonata® (zaleplon) capsules
 
•  TriCor®145 (fenofibrate) tablets
 
•  Zanaflex® (tizanidine)
 
•  Zonegran® (zonisamide) capsules

     
Elan Corporation, plc 2008 Annual Report
  193


Table of Contents

 
 
Shareholder and Other Information
 
Elan Corporation, plc, is an Irish registered company with primary listings on the Irish Stock Exchange and the London Stock Exchange. Our ADSs are listed on the NYSE (Symbol: ELN). Each ADS represents one ordinary share.
 
 
This excerpt taken from the ELN 6-K filed Mar 31, 2008.
Documents on Display
 
The Company is subject to the reporting requirements of the Exchange Act. In accordance with these requirements, the Company files Annual Reports on Form 20-F with, and furnishes Reports of Foreign Issuer on Form 6-K to, the SEC. These materials, including our Annual Report on Form 20-F for the fiscal year ended 31 December 2007 and the exhibits thereto, may be inspected and copied at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington D.C. 20549. Copies of the materials may be obtained from the Public Reference Room of the SEC at 100 F Street, NE, Room 1580, Washington, D.C. at prescribed rates. The public may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC in the United States at 1-800-SEC-0330. As a foreign private issuer, all documents which were filed or submitted after 4 November 2002 on the SEC’s EDGAR system are available for retrieval on the website maintained by the SEC at http://www.sec.gov. These filings and submissions are also available from commercial document retrieval services.
 
Copies of our Memorandum and Articles of Association may be obtained at no cost by writing or telephoning the Company at our principal executive offices. Our Memorandum and Articles of Association are filed with the SEC as Exhibit 4.1 of our Registration Statement on Form S-8 (SEC File No. 333-135185) filed with the SEC on 21 June 2006. You may also inspect or obtain a copy of our Memorandum and Articles of Association using the procedures prescribed above.

Elan Corporation, plc 2007 Annual Report 153


Table of Contents

 
 
Trademarks
 
The following trademarks appearing in this publication are owned by or licensed to the Company:
 
•  Azactam® (aztreonam for injection, USP)
 
•  Maxipime® (cefepime hydrochloride) for injection
 
•  NanoCrystal® Technology
 
•  Naprelan® (naproxen sodium controlled-release) tablets
 
•  Prialt® (ziconotide intrathecal infusion)
 
•  Tysabri® (natalizumab)
 
•  Verelan® (verapamil) capsules
 
Third-party marks appearing in this publication are:
 
•  Adalat®CC (nifedipine) tablets
 
•  Avinza® (morphine sulfate extended-release) capsules
 
•  Avonex® (Interferon beta-1A)
 
•  Betaseron® (interferon beta-1b)
 
•  Copaxone® (glatiramer acetate injection)
 
•  Crestor® (rosuvastatin calcium)
 
•  Emend® (aprepitant)
 
•  Focalin®XR (dexmethylphenidate)
 
•  Megace® ES (megastrol acetate)
 
•  Rapamune® (sirolimus)
 
•  Rebif® (interferon-beta-1a)
 
•  RitalinLA® (methylphenidate hydrochloride) tablets
 
•  Skelaxin® (metaxalone) tablets
 
•  Sonata® (zaleplon) capsules
 
•  TriCor® (fenofibrate) tablets
 
•  Zonegran® (zonisamide) capsules

154 Elan Corporation, plc 2007 Annual Report


Table of Contents

 
 
Shareholder and Other Information
 
Elan Corporation, plc is an Irish registered company with primary listings on the Irish Stock Exchange and the London Stock Exchange. Our ADSs are listed on the NYSE (Symbol: ELN). Each ADS represents one ordinary share.
 
 
This excerpt taken from the ELN 6-K filed Mar 30, 2007.
Documents on Display
 
The Company is subject to the reporting requirements of the Exchange Act. In accordance with these requirements, the Company files Annual Reports on Form 20-F with, and furnishes Reports of Foreign Issuer on Form 6-K to, the SEC. These materials, including our Annual Report on Form 20-F for the fiscal year ended 31 December 2006 and the exhibits thereto, may be inspected and copied at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington D.C. 20549. Copies of the materials may be obtained from the Public Reference Room of the SEC at 100 F Street, NE, Room 1580, Washington, D.C. at prescribed rates. The public may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC in the United States at 1-800-SEC-0330. As a foreign private issuer, all documents which were filed or submitted after 4 November 2002 on the SEC’s EDGAR system are available for retrieval on the website maintained by the SEC at http://www.sec.gov. These filings and submissions are also available from commercial document retrieval services.
 
Copies of our Memorandum and Articles of Association may be obtained at no cost by writing or telephoning the Company at our principal executive offices. Our Memorandum and Articles of Association are filed with the SEC as Exhibit 4.1 of our Registration Statement on Form S-8 (SEC File No. 333-135185) filed with the SEC on 21 June 2006. You may also inspect or obtain a copy of our Memorandum and Articles of Association using the procedures prescribed above.
 
152 Elan Corporation, plc 2006 Annual Report


Table of Contents

 
 
Trademarks
 
 
The following trademarks appearing in this publication are owned by or licensed to the Company:
 
•  Azactam® (aztreonam for injection, USP)
 
•  Maxipime® (cefepime hydrochloride) for injection
 
•  NanoCrystal® Technology
 
•  Naprelan® (naproxen sodium controlled-release) tablets
 
•  Prialt® (ziconotide intrathecal infusion)
 
•  Tysabri® (natalizumab)
 
•  Verelan® (verapamil) capsules
 
Third-party marks appearing in this publication are:
 
•  Adalat®CC (nifedipine) tablets
 
•  Avinza® (morphine sulfate extended-release) capsules
 
•  Avonex® (Interferon beta-1A)
 
•  Betaseron® (interferon beta-1b)
 
•  Copaxone® (glatiramer acetate injection)
 
•  Crestor® (rosuvastatin calcium)
 
•  Emend® (aprepitant)
 
•  Focalin®XR (dexmethylphenidate)
 
•  Megace® ES (megastrol acetate)
 
•  Rapamune® (sirolimus)
 
•  Rebif® (interferon-beta-1a)
 
•  RitalinLA® (methylphenidate hydrochloride) tablets
 
•  Skelaxin® (metaxalone) tablets
 
•  Sonata® (zaleplon) capsules
 
•  TriCor® (fenofibrate) tablets
 
•  Zonegran® (zonisamide) capsules
 
Elan Corporation, plc 2006 Annual Report 153


Table of Contents

 
 
Shareholder Services
 
 
Our ADSs are listed on the NYSE (Symbol ELN). Our Ordinary Shares are listed on the Official Lists of the London and Irish Stock Exchanges.
 
This excerpt taken from the ELN 6-K filed Mar 31, 2006.
Documents on Display
The Company is subject to the reporting requirements of the Exchange Act. In accordance with these requirements, the Company files Annual Reports on Form 20-F with, and furnishes Reports of Foreign Issuer on Form 6-K to, the SEC. These materials, including our Annual Report on Form 20-F for the fiscal year ended 31 December 2005 and the exhibits thereto, may be inspected and copied at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington D.C. 20549. Copies of the materials may be obtained from the Public Reference Room of the SEC at 100 F Street, NE, Room 1580, Washington, D.C. at prescribed rates. The public may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC in the United States at 1-800-SEC-0330. As a foreign private issuer, all documents which were filed or submitted after 4 November 2002 on the SEC’s EDGAR system are available for retrieval on the website maintained by the SEC at http://www.sec.gov. These filings and submissions are also available from commercial document retrieval services.
Copies of our Memorandum and Articles of Association may be obtained at no cost by writing or telephoning the Company at our principal executive offices. Our Memorandum and Articles of Association are filed with the SEC as Exhibit 3 of our Registration Statement on Form 8-A/ A3 (SEC File No. 001-13896) filed with the SEC on 6 December 2004. You may also inspect or obtain a copy of our Memorandum and Articles of Association using the procedures prescribed above.
170 Elan Corporation, plc 2005 Annual Report


Table of Contents

Directors, Senior Management and Other Information
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki